Provision of the progestogen-only pill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT

Sharon T Cameron,^{1,2*} Anna Glasier,¹ Lisa McDaid,^{3,4} Andrew Radley,^{5,6} Susan Patterson,⁴ Paula Baraitser,⁷ Judith Stephenson,⁸ Richard Gilson,⁹ Claire Battison,¹⁰ Kathleen Cowle,¹¹ Thenmalar Vadiveloo,¹² Anne Johnstone,¹ Alessandra Morelli,⁷ Beatriz Goulao,¹² Mark Forrest,¹² Alison McDonald¹² and John Norrie¹⁰

Declared competing interests of authors: Anna Glasier is a member of the HRA Pharma's (London, UK) scientific advisory board. Lisa McDaid and Susan Patterson are funded by the UK Medical Research Council (London, UK) and Scottish Government Chief Scientist Office (Edinburgh, UK) at the Medical Research Council/Chief Scientist Office Social and Public Health Sciences Unit, University of Glasgow (Glasgow, UK) (MC_UU_12017/11, SPHSU11). Andrew Radley holds research grants, educational grants and consultancy with Gilead Sciences, Inc. (Foster City, CA, USA), research grants from Roche (Basel, Switzerland) and

¹Obstetrics and Gynaecology, University of Edinburgh, Edinburgh, UK

²Sexual and Reproductive Health, NHS Lothian, Edinburgh, UK

³Institute for Social Science Research, The University of Queensland, Brisbane, QLD, Australia

⁴Medical Research Council/Chief Scientist Office Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK

⁵Directorate of Public Health, NHS Tayside, Dundee, UK

⁶Division of Cardiovascular Medicines and Diabetes, Ninewells Hospital and Medical School, Dundee, UK

⁷Department of Sexual Health, King's College Hospital NHS Foundation Trust, London, UK

⁸Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK

⁹Institute for Global Health, University College London, London, UK

¹⁰Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK

¹¹Community pharmacy, NHS Forth Valley, UK

¹²Health Services Research Unit, University of Aberdeen, Aberdeen, UK

^{*}Corresponding author sharon.cameron@ed.ac.uk

Bristol Myers Squibb™ (New York, NY, USA), and educational grants from AbbVie (North Chicago, IL, USA). Paula Baraitser is a clinical director of the not-for profit community interest company SH:24 (London, UK), which provides online sexual health services in partnership with the NHS. Kathleen Cowle was an employee of Boots UK (Nottingham, UK) during the course of the study. Alessandra Morelli was a clinical bank midwife of the not-for-profit community interest company SH:24 (October 2019–January 2021). She is also a research midwife at the University of Oxford (Oxford, UK). John Norrie is deputy chairperson of the National Institute for Health Research Health Technology Assessment General Board Committee. He was a member of the Health Technology Assessment and Efficacy and Mechanism Evaluation Editorial Board (2014–19).

Published May 2021 DOI: 10.3310/hta25270

Plain English summary

The Bridge-it RCT

Health Technology Assessment 2021; Vol. 25: No. 27

DOI: 10.3310/hta25270

NIHR Journals Library www.journalslibrary.nihr.ac.uk

Plain English summary

The emergency contraceptive pill can prevent pregnancy following unprotected sex or a burst condom; however, unless women start a regular method of contraception they remain at risk of pregnancy. Most women obtain emergency contraception from a community pharmacy (chemist), but then require an appointment with a general practitioner or at a sexual and reproductive health clinic for ongoing contraception. Getting an appointment can take time and unintended pregnancies can occur during this time.

If a pharmacist could give women a small supply of a progestogen-only pill or 'mini-pill' with their emergency contraception, together with help to get an appointment at a clinic, then this might help more women to start effective contraception.

We undertook a study in 29 pharmacies in Lothian, Tayside and London among women receiving emergency contraception. Pharmacists provided either their standard advice about contraception (control group) or the intervention. The intervention was a 3-month supply of the progestogen-only pill plus a rapid-access card, which, if presented at a sexual and reproductive health clinic, would help women get an appointment for contraception. The order in which the pharmacy provided either control or intervention was randomised. We conducted telephone interviews with the women 4 months later to find out what contraception they were using.

A total of 636 women took part in the study, 316 in the intervention group and 320 in the control group. The proportion who said that they were using an effective method of contraception was around 20% larger in the intervention group. In addition, fewer women in this group said that they had used emergency contraception again. This study shows that community pharmacy provision of a small supply of progestogenonly pills and the invitation to attend a sexual and reproductive health clinic results in a large increase in the use of effective contraception after emergency contraception. If this became routine practice then it could help prevent unintended pregnancies.

Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 3.370

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 15/113/01. The contractual start date was in April 2017. The draft report began editorial review in July 2020 and was accepted for publication in January 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2021. This work was produced by Cameron *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

NIHR Journals Library Editor-in-Chief

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk